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Cell-Derived Factor 1 Expression
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Treatment of critical size bone defects pose a challenge in orthopedics. Stem cell therapy together with
cytokines has the potential to improve bone repair as they cause the migration and homing of stem cells to the
defect site. However, the engraftment, participation, and recruitment of other cells within the regenerating tissue
are important. To enhance stem cell involvement, this study investigated overexpression of stem cells with
stromal cell-derived factor 1 (SDF-1) using an adenovirus. We hypothesized that these engineered cells would
effectively increase the migration of native cells to the site of fracture, enhancing bone repair. Before im-
plantation, we showed that SDF-1 secreted by transfected cells increased the migration of nontransfected cells.
In a rat defect bone model, bone marrow mesenchymal stem cells overexpressing SDF-1 showed significantly
( p = 0.003) more new bone formation within the gap and less bone mineral loss at the area adjacent to the defect
site during the early bone healing stage. In conclusion, SDF-1 was shown to play an important role in
accelerating fracture repair and contributing to bone repair in rat models, by recruiting more host stem cells to
the defect site and encouraging osteogenic differentiation and production of bone.
Introduction
Skeletal injuries and their complications are majorcauses of morbidity and mortality, and this problem is
highlighted in patients with osteoporosis and related frac-
tures.1 Each year,*7.9 million fractures occur in the United
States, and of these, up to 10% result into delayed union or
nonunion.2–5 In the United Kingdom, there are about 150,000
wrist, vertebral, and hip fractures yearly due to osteoporosis
with an estimated health care cost of £17 billion per annum.6
Stem cell therapy has been used in the treatment of difficult
cases, such as nonunion fractures and for treating large bone
defects, and so far, results have been promising.7 For suc-
cessful bone repair, an environment of biomechanical stability
and biological vitality are very important. Bone repair can be
impaired by insufficient vascularization, infection, mechani-
cal instability, and systemic diseases.8 Mesenchymal stem
cells (MSCs) under the correct conditions and signals can
differentiate into tissues, such as bone cartilage, tendon,
muscle, ligament, and marrow stroma.9 During the fracture
healing process, MSCs migrate into the fracture site from
blood, periosteum, bone marrow (BM), and other tissue ni-
ches. The MSCs then proliferate and differentiate into osteo-
blasts and chondrocytes.10 The osteoblasts from the cortex and
osteoprogenitor cells from the periosteum proliferate and dif-
ferentiate to form immature bone. This immature bone even-
tually forms a bridge of mineralized woven bone between the
fracture fragments.11–13
One of the methods used to heal fractures is to percutane-
ously inject adult stem cells isolated from the BM preopera-
tively. The intention of this procedure is to create an osteogenic
response, which would enhance the rate and amount of bone
formation. Due to the age of an individual, aspiration site, and
the techniques used, there is variability in the number of stem
cells available for repair.10,14,15 Additionally, in the BM, it
has been calculated only 1–10 cells per 100,000 cells are
MSCs. Cellular movement has been identified as important in
neovascularization, wound healing, and organ repair. Sig-
naling molecules have been identified to play important roles
in maintaining the mobilization, trafficking, and homing of
stem cells.16
During organ regeneration, it has been suggested that
local MSCs derived from the injured tissue and circulating
MSCs work together in healing damaged organs. Stem cells
sense the tissue injury, migrate to the site of the damage, and
undergo differentiation,7,17 and this may explain the larger
numbers of stem cells found in damaged tissues compared to
normal healthy tissues, such as impaired sites in the brain
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after hypoglossal nerve injury18 and cerebral injury.19 As a
result of injury, the surviving cells may produce chemoat-
tractants such as stromal cell-derived factor 1 (SDF-1) that
may direct the migration of MSCs to the injury site.19
Chemokines are a group of small proteins (8–14 kDa) char-
acterized as being able to direct the movement of receptor-
presenting cells toward higher concentrations of chemokines
in the environment.20 The chemokine SDF-1 (also known as
CXCL12) is produced inmany organs bymultiple BM stromal
cell types and epithelial cells. It is known to play important
roles in the migration of hematopoietic stem cells to the BM.
The binding of SDF-1 to CXCR4 initiates a signaling pathway,
which causes such responses as cell division and increased
metabolic activity. The SDF-1 CXCR4 interaction is believed
to hold stromal cells in the BM niche.16,21–23
Enhancing fracture healing using stem cells would be
beneficial, and the hypothesis of our study was that bone
growth in fracture site is enhanced by the local delivery
of MSCs overexpressing SDF-1 when compared to non-
transduced MSCs in a rat model. The aim of the study was
to improve fracture healing using stem cells by enhancing
local SDF-1 protein levels in the fracture site.
Methodology
Cell culture
Rat bone marrow mesenchymal stem cells (rBMC) were
harvested from 8 week young adult male Wistar rats. Rats
were sacrificed by cervical dislocation and the BM cells were
harvested by flushing the femora with Dulbecco’s modified
Eagle medium (DMEM), 10% fetal calf serum, 1% penicillin
streptomycin (Sigma-Aldrich) in a 25-cm2 flask after being
pumped through the Ficoll gradient. The cells were cultured at
37C and 5% CO2. Media were changed after 4 days to re-
move the nonadherent cells and then continuously refreshed
twice a week thereafter. After 10–14 days of primary culture,
when the cells were 70–80% confluent, they were passaged
using trypsin–ethylenediaminetetraacetic acid (EDTA; Sigma-
Aldrich). Cells were then passaged about every 7–8 days.
Passage 4 and 5 cells were used for the studies. Additionally,
these cells were positively differentiated into adipocytes,
chondrocytes, and osteoblasts using the trilineage differenti-
ation protocol and characterized using FACS to show positive
expression for CD29, CD44, CD73, CD90, CD105, and CD71
and negative for CD13, CD45, and CD34.24,25
Preparation of recombinant adenovirus
The human SDF-1 cDNA (obtained from the National
Yang-Ming University VYM Genome Research Centre) was
digested by restriction endonucleases NotI and XhoI and then
inserted into pShuttle-CMV (AdEasy XL Adenoviral vector
system; Stratagene) to form pShuttle-CMV-SDF1. Human
SDF-1 gene and the pShuttle-CMV vector were cut by re-
striction endonuclease NotI and XhoI to form sticky ends.
Human SDF-1 cDNA was then cloned into the pShuttle-
CMV vector through the matches of NotI and XhoI cutting
sides using Taq DNA ligase. The incorporated shuttle vector
was then linearized with PmeI restriction endonuclease and
transformed into BJ5183-AD-1 competent cells. After iden-
tifying the recombinants, its copies were largely expanded in
bulk using the recombinant-deficient XL 10-Gold strain.
Purified recombinant plasmid DNA was then used to trans-
fect AD-293 cells, which were then used to transfect the
rBMCs. The SDF-1 overexpressing rBMCs (rBMC-SDF-1)
were engineered by infection of adenovirus carrying human
SDF-1 gene at a multiplicity of infection (MOI) of 500. The
infection rate was 70%.
Virus titer determination and cell infection
Thirty thousand rBMCs (Passage 5) were seeded in each
well of 24-well plates and cultured at 37C overnight. Cells
were then infected by adenovirus expressing human SDF-1a
(Ad-SDF-1) with a MOI ranging from 0 to 500 (six replicates
for each MOI group). After 2 days in the normal culture
medium, the medium was changed to serum-free DMEM
for 3 days. The concentration of secreted SDF-1 in the me-
dium was detected by enzyme-linked immunosorbent assay
(ELISA) of SDF-1, which was measured by absorbance of
450 nm wavelength (R&D Systems). To test the tolerance of
the cells for adenovirus infection and the most efficient MOI,
the cells were infected with Ad-LacZ separately and the b-
galactosidase activity of cells was measured.
In vitro chemotaxis assay
For this in vitro study, a transwell chamber consisting of
a polycarbonate membrane with 0.8 mm porosity (Corning,
Fisher Scientific) was used. Thirty thousand rBMCs (Pas-
sage 4) were seeded in 24-well plates at the bottom of the
chamber and cultured at 37C in an incubator overnight in
the normal medium. Cells were infected with Ad-SDF-1 by
various MOI of 0, 250, and 500 and cultured in the normal
medium, in each separate well plate. On the fourth day
after infection, 4500 cells were seeded on the upper surface
of the transwell chamber and cultured at 37C in an in-
cubator. After 5 days, the upper chambers containing the
untransfected rBMCs were placed into the well plates
seeded with rBMCs. Cells that migrated to the opposite
side of the membrane after 6 h were fixed, stained with
toluidine blue, and counted.
Bone formation—fracture model
Eighteen adult female rats, weighing between 200 and
250 g, were anesthetized by inhalation of isoflurane and the
left femur shaved and disinfected. A critical size of 3mm
gap in the middle of the femur was created during the sur-
gery and stabilized by an external fixator (Fig. 1). The rats
were divided into three groups with six rats in each group:
(1) rBMC-SDF-1, (2) rBMC, and (3) control. In two groups,
300,000 rBMCs or rBMC-SDF-1 were seeded into a colla-
gen type I sponge (4 · 4· 7mm) (Helistat; COLLA-TEC)
and transplanted into the gap. In the control group, sponges
without cells were used. The wound was then closed layer
by layer and antibiotics and analgesics administered post-
surgery. Rats were sacrificed 3 weeks later and the femora
harvested. The osteotomy was stabilized by an external
fixator attached to the two parts of the femur by 4 · 1-mm-
diameter titanium pins. A material test machine was used
to check that the variability in stiffness between different
fixators was less than 5%. A standard fixator stiffness was
maintained by ensuring that the crossbeam of the fixator was
a consistent distance from the femoral surface.
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A second experiment studied the direct administration of
Ad-SDF-1. In the Ad-SDF-1 group, 1.2· 108 Ad-SDF-1 virus
particles were suspended in 200mL culture medium, which was
soaked onto the collagen sponge. The other three groups were
the same as the groups in the 3 weeks short-term experiment. In
these groups, animals were kept alive for 6 weeks.
Analysis of bone formation
Bone mineral content (BMC) and bone mineral density
(BMD) were measured in a consistent region by dual-energy
X-ray absorptiometry (DEXA) scan (QDR-1000; Hologic) at
the first, third, and where appropriate the sixth week after
operation. An extra high-resolution program was used. A
constant area was analyzed, which included the osteotomy
with parts of the original bone and peripheral bone formed
adjacent to the gap for the BMD. The results were generated
by adding the measurements from the proximal and distal
analyzing boxes (Fig. 1). Inhalation anesthesia was given to
the rats before and during the scan. The rat’s left leg was fixed
by a clamp, which held the external fixator, in the same po-
sition during DEXA scanning at each time point. The area of
new bone formation was measured using histomorphometry
on hematoxylin and eosin-stained sections. After the rats were
sacrificed, the left femur was retrieved. The specimens were
fixed in 10% formal saline, dehydrated by a series of alcohol,
and decalcified by EDTA. Decalcification was confirmed by
radiography. After decalcification, specimens were dehy-
drated, treated with chloroform, and then embedded in wax.
Samples were labeled on the longitudinal middle line of the
femur before being embedded in wax to indicate the location
of the sectioning area. A microtome was then used to create 7-
mm-thick sections. The sections were then quantified using an
imaging analysis system.
The maintenance of the donor cells within the fracture site
after 3 weeks was measured by fluorescence in situ hybrid-
ization (FISH) staining of the Y chromosome and is shown in
ratio standardized by the rBMC group. FISHwas performed by
a commercial kit (Cambio), which was costained with 4¢,6-
diamidino-2-phenylindole. The probe of the rat Y-chromosome
was denatured and a prewarmed probe was added to the cell
samples, followed by a detection solution. After the samples
were washed by the detergent wash solution, they were viewed
under a fluorescence microscope (KS-300; Zeiss).
Statistical analysis
Results were analyzed with one-way analysis of variance
(ANOVA) test. p values £ 0.05 were considered significant.
For ANOVAs with significant F tests, a Tukey’s post hoc
procedure was performed to compare the significance be-
tween the two groups.
Results
SDF-1 infection
SDF-1 expression in rBMCs was estimated on the fifth
day after the infection by Ad-SDF-1 of various MOI (Fig. 2).
rBMCs infected with different MOIs of Ad-LacZ ranging
from 0 to 500 was used to determine the tolerance of the
cells to the adenovirus infection. The b-galactosidase activity
of cells was tested. An increasing amount of positively blue
cells was observed in the MOI groups higher than 175, with
the highest number of blue cells at a MOI of 500.
Additionally, the concentration of the secreted SDF-1 in
the medium, after the transfection, was detected by ELISA.
The expression of SDF-1 was significantly upregulated
( p = 0.007) using a MOI 125 and reached the maximum at a
MOI of 500 with an infection rate of 70%. No severe cell
damage was observed for the different MOI of SDF-1.
In vitro chemotaxis assay
A transwell migration assay was performed to examine
whether secreted SDF1 could successfully increase cell migra-
tion toward the infected cells in a dose-dependent manner.
The rBMCs showed significant (p=0.011) and dose-dependent
FIG. 1. A 3-mm osteotomy
created in the femur of a rat
(left) and an analyzing box for
bone mineral content (BMC)
and bone mineral density
(BMD) measurement (right).
Color images available online
at www.liebertpub.com/tea
FIG. 2. Stromal cell-derived factor 1 (SDF-1) expression
of rat bone marrow mesenchymal stem cells (rBMCs) 5 days
after Ad-SDF-1 infection with different multiplicity of in-
fection. Data points sharing different Tukey’s letters are
significantly different ( p< 0.05).
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chemoattractive activity to Ad-SDF-1-infected stem cells at the
bottom of the chamber (Fig. 3). Furthermore, two times more
cells migrated to the opposite side of the membrane in the MOI
250 group and even larger numbers with the MOI 500 group.
Bone mineralization
Bone mineral content. It has been suggested that SDF1/
CXCR4 signaling is a principal axis in the retention, migra-
tion, and repopulation of stem cells during homeostasis and
injury. We therefore investigated whether stem cells over-
expressing SDF1 would enhance bone formation at a defect
site. BMC of the osteotomy area was measured following
DEXA scanning. The rBMC-SDF-1 group showed signifi-
cantly increased BMC than both the control and rBMC
groups ( p = 0.003 and p= 0.0029, respectively) (Fig. 4), and
this could be due to the maintenance of the donor cells in the
osteotomy, which was measured by FISH after 3 weeks. The
rBMC-SDF-1 group showed about 2.5-fold more donor cells
than the rBMC group in the fracture site.
BMC and BMD were measured every 3 weeks during the
experiment. The rBMC-SDF-1 group showed an almost four
times BMC increase when compared with the control group
( p= 0.008), and a higher increase when compared with the
rBMC group ( p= 0.088) (Fig. 5). After 3 weeks (from the
fourth week to the sixth week), all groups showed a decrease
in BMC (Fig. 5). However, the rBMC-SDF-1 group dem-
onstrated the least decrease compared with the control group
( p= 0.08). The change after 6 weeks showed that only the
rBMC-SDF-1 group had an increased BMC compared with
the control group ( p = 0.003) (Fig. 5).
Bone mineral density. The BMD change in the periph-
eral bone adjacent to the osteotomy gap was also measured
at 3 and 6 weeks. Both the rBMC-SDF-1 and Ad-SDF-1
groups showed increased BMD in the first 3 weeks while the
control and rBMC groups showed reduced density (Fig. 6).
During the second 3 weeks, all groups showed further BMD
loss. Although there was no significant difference in BMD
change among all groups after 6 weeks (Fig. 6), the rBMC-
SDF-1 group had the least BMD loss compared with the
control group ( p = 0.167) and the rBMC group ( p = 0.140).
FIG. 3. Cell migration due to the secreted SDF-1 in Ad-
SDF-1-infected rBMCs. Data points sharing different Tu-
key’s letters are significantly different ( p< 0.05).
FIG. 4. Radiographs of
osteotomy site after 3 weeks
(A), fluorescence in situ hy-
bridization (FISH) staining
showing the donor cells
(400· ). The male Y chro-
mosomes staining are shown
in red and the nuclei are
shown in blue (B) and the
ratio of cell numbers with the
FISH staining for the differ-
ent controls (C). Color ima-
ges available online at www
.liebertpub.com/tea
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New bone formation
Histology of the osteotomy site after 3 weeks showed new
bone formation in all three groups with the rBMC-SDF-1
group showing greatest amounts of new bone formation.
The rBMC-SDF-1 group produced significantly more new
bone than the rBMC group ( p= 0.02), but no significant
difference was seen when compared with the control group
( p = 0.08). No significant difference was found when the
control and rBMC groups were compared ( p= 0.8). New
bone formation in most defects in the control group was
only found on one side of the fracture, whereas in the other
two groups, bone formation was more uniform (Fig. 7).
New bone formation after 6 weeks showed a similar trend
to the new bone formation observed in the 3-week experi-
ment. Highest amounts of new bone had formed in the rBMC-
SDF-1 group when compared with all other groups ( p = 0.029
with control group). Additionally, increased bone formation
was measured in the Ad-SDF-1 group when compared with
the control group, but values obtained were lower than that
found in defects containing the rBMC-SDF-1 and with those
in the rBMC group. However, no significant differences were
found when these groups were compared (Fig. 8).
Discussion
In this study, we have demonstrated that MSCs transfected
with the SDF1 gene secreted greater levels of this protein and
that in vivo this leads to increased MSC migration. These
cells when incorporated into the fracture site led to enhanced
fracture healing. This may be associated with the retention of
MSCs in the fracture site and mobilization of nontransfected
cells into this site. Cellular movement and relocalization are
crucial for many important physiological properties, such as
embryonic development, neovascularization and angiogene-
sis, immunologic responses, wound healing, and organ repair.
Both local MSCs from the injured tissue and circulating MSCs
collaborate in the healing of organs during organ regeneration,
and this cell movement is regulated by chemotaxis, which
causes directional migration through signaling molecules called
chemokines.7,26 Recruitment of stem cells to areas of bone
damage is therefore an important modality for the repair and
remodeling process.27 The potential of MSCs for bone repair
have been investigated extensively in various studies because
these cells play important roles in skeletal homeostasis.28,29
FIG. 5. BMC change within the osteotomy site after 3
weeks (A), BMC change after 6 weeks (B), and BMC
change from the fourth week to the sixth week (C) (*sig-
nificant difference p £ 0.05).
FIG. 6. BMD change from the first week to the third week
(top) BMD change of the original bone area adjacent to the
osteotomy gap after 6 weeks (mean – standard deviation)
(bottom).
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FIG. 7. Hematoxylin and
eosin (H&E) staining of new
bone formation (200· ) (top)
and new bone area in the
osteotomy (bottom) after 3
weeks (*significant differ-
ence p£ 0.05). Color images
available online at www
.liebertpub.com/tea
FIG. 8. H&E staining of new bone formation (200 · ) (top) and new bone area in the osteotomy (bottom) after 6 weeks
(*significant difference p £ 0.05). Color images available online at www.liebertpub.com/tea
ROLE OF SDF-1 IN FRACTURE HEALING IN RATS 599
We investigated the chemotaxis ability of stem cells
in vitro using a Boyden chamber. The number of stem cells
that migrated to the opposite side of the membrane in-
creased in a dose-dependent manner. A higher SDF-1 con-
centration was secreted by the cells with a MOI of 500 and
therefore caused more cells to migrate toward it. A similar
study by Wynn et al.23 found that maximum migration oc-
curred at an SDF-1 concentration of 30 ng/mL and a neu-
tralizing anti-CXCR4 antibody inhibited MSC migration by
*46%. This shows that MSCs express functionally active
CXCR4 receptors, which cause the migration of MSCs to
the BM. However, it was found that the CXCR4 receptor is
present at low levels on the cell surface of MSCs, and to
improve the engraftment of MSCs to BM and bone, an in-
crease in its functional expression may be required.23
After 3 weeks, the rats transplanted with stem cells ex-
pressing SDF1 (rBMC-SDF-1 group) had increased new bone
formation, BMC, and density. rBMC-SDF-1 not only in-
creased new bone formation but also showed significantly
higher BMC after 3 weeks compared to the control group.
Additionally, more donor cells were found in the compact new
bone in the rBMC-SDF-1 group compared to the control
groups. This bone healing progressmay be due to the enhanced
local SDF-1/CXCR4 interaction that recruited more host
stem cells into the fracture site. Similar studies have shown
that SDF1 recruits MSCs to the periosteum of the injured bone
and therefore promote endochondral bone repair.28 The
CXCR4/SDF1 signaling pathway has been reported to play a
critical role in bone healing as it affects cell migration and
differentiation to the defect site as well as affecting the nu-
merous cellular processes involved in bone healing, such as
chondrogenesis and osteogenesis, bone remodeling, and
vascularization.30 Our previous study also showed that SDF-1
could enhance the osteoblastic differentiation of human
MSCs, which may additionally contribute to new bone for-
mation. When cells were cultured with SDF-1 and os-
teoinductive medium, they showed a significantly higher
alkaline phosphatase (ALP) activity compared to cells that
were cultured in the osteoinductive medium alone, indicating
an enhanced osteogenic differentiation.31
The control group, in which no cells were transplanted
into the defect site, showed an increase in new bone for-
mation following histological analysis, but a reduced BMC
after 3 weeks. On the other hand, the rBMC group, which
consisted of only stem cells transplanted into the defect site,
showed similar new bone area but higher BMC compared to
the control group. This implies that BMCs initiate faster
bone regeneration. Both rBMC and rBMC-SDF-1 groups had
a higher BMC and a more compact new bone showing en-
hancement of bone mineralization by the transplanted stem
cells. Granero-Molto et al.32 has shown that implanted MSCs
migrated to a fracture site, and this migratory capacity of
stem cells may be driven by CXCR4. Similar to this study,
they also reported that mice transplanted with MSCs at a
fracture site displayed a significant increase in total volume,
as well as total bone, soft tissue, new bone and callus vol-
umes, and callus mineralization content, in comparison to the
control group. The MSC transplant improved the fracture
healing by increasing the material toughness of the callus
and causing it to be less brittle.32
During endochondral bone repair, SDF-1 expression is
upregulated by progenitor cells in the periosteum and this
results in recruitment of MSCs.28 Additionally, other growth
factors could direct the formation of bone in the early stages
of bone repair. Vascular endothelial growth factor has been
shown to be upregulated in the initial stages of fracture
healing, improving angiogenesis, leading to conversion of soft
cartilaginous callus to hard bony callus.33–35 This could ex-
plain the increased new bone formation seen at the defect site,
although no cells were transplanted there. Additionally, SDF1
could also enhance the early osteogenic differentiation of stem
cells, mediated by a bone morphogenic protein (BMP) sig-
naling pathway. A study by Hosogane et al.36 showed that
blocking of the SDF-1/CXCR4 signal axis or adding SDF-1
protein to MSCs significantly affected BMP2-induced ALP
activity and osteocalcin synthesis. Bone nodule mineralization
decreased as well when the SDF-1 signaling was disrupted.
They also showed that blocking the SDF-1 signaling inhibited
the expression of Runt-related factor-2 and osterix, two im-
portant regulators of osteogenesis.36
The key drivers to bone healing are cytokines, platelets,
and growth factors, of which BMPs have been recognized as
critical players. BMP2 and transforming growth factor
(TGF) b are required for normal fracture healing, and in
their absence, MSCs at the repair site do not differentiate
toward the osteogenic lineage, leading to a failed healing
response of the bone. It has been shown that levels of BMP
receptors present on the callus cells increase early in the
repair process. However around day 10–20, the levels of
BMP receptors begin to decrease as the callus cells differ-
entiate and robust bone formation occurs. Similar results
have also been observed with TGFb as callus formation
increases.27,37–40 During the 6 week experiment, all groups
showed an increase in BMC during the first 3 weeks fol-
lowed by its reduction during the second 3 weeks, which is
in contrast to a typical bone healing procedure in a critical
size bone defect model. By enhancing the local SDF-1 level,
the rBMC-SDF-1 group showed significantly higher BMC
and more new bone formation than the control and rBMC
group at both 3 and 6 weeks postoperatively. Interestingly,
although control animals had a higher BMC at 3 weeks and
they lost that gain at 6 weeks, the rBMC-SDF-1 group
gained the most and lost the least amount of BMC. The large
standard errors in the rBMC group at 6 weeks could be due
to less bone formation in one of the samples in this group. It
is also important to note that the expression period of ade-
noviral vector is about 3–4 weeks,41 so future studies could
possibly look at upregulating the local SDF1 levels by
multiple administrations of adenovirally infected MSCs.
In summary, this study demonstrated that SDF1 plays an
important role in fracture repair. SDF1 recruited MSCs toward
the defect site, initiating bone repair. However, several ques-
tions need to be answered, before this approach can be used in
clinical settings. In light of the previous data on the effect of
stem cells on fracture healing, it has been shown in this study
that there was a trend, which was not significant. However, the
effect of SDF-1 transduced BM cells was significant. This
may indicate the very positive effect SDF1 has and fracture
models can produce different results depending on a number
of variables. In this study, we have used controls of non-
transduced stem cells and defects where no stem cells were
used. As the untransfected cells had no effect, this model is
probably extreme but still shows the effect of recombinant
rBMC. Moreover, in this study, plasmid-alone transfected or
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scrambled SDF-1 DNA was not utilized. However, due to the
fact the transfected cells in vitro overexpressed SDF-1 and
had a positive effect in vivo, we therefore believe that this
was due to SDF-1 production and was not associated with
the transfection technique. Although we have shown that
transfected MSCs overexpress SDF-1 in vitro, we did not
show that these cells continued to produce SDF-1 when
implanted in vivo. It would have been interesting to compare
the in vivo levels of SDF-1 from the four groups, using
immunohistochemistry and/or qPCR for SDF-1 on the tis-
sues. We have, however, shown the effects these transfected
cells had on fracture healing, and our results suggest that this
is due to these cells overexpressing SDF-1.
One of the limitations of this study was we measured bone
using an area algorithm, whereas micro-CT would give vol-
ume. Micro-CT could possibly have been a more accurate
measure of bone formation. Another limitation of this study
includes the use of adenovirus. Even if the adenoviral vectors
have been established to be replication defective and offer
many advantages in gene therapy, they could trigger strong
immune responses in humans. These vectors could also cause
local damage and inflammation.25,42 Hence, if this approach
was used for the treatment of deficient bone, a more im-
proved approach to deliver SDF-1 must be evaluated.
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